Objective-Myeloperoxidase, a heme enzyme that is present and active in human atherosclerotic lesions, provides a source for the generation of proinflammatory chlorinated reactants contributing to endothelial dysfunction. Modification of high-density lipoprotein (HDL) by hypochlorous acid/hypochlorite (HOCl/Oce Ϫ )-generated in vivo by the myeloperoxidase-hydrogen peroxide-chloride system of activated phagocytes-forms a proatherogenic lipoprotein particle that binds to and is internalized by endothelial cells. Methods and Results-Here we show that HDL, modified with physiologically relevant HOCl concentrations, attenuates the expression and activity of vasculoprotective endothelial nitric oxide synthase. HOCl-HDL promotes dislocalization of endothelial nitric oxide synthase from the plasma membrane and perinuclear location of human umbilical venous endothelial cells. We could identify 2-chlorohexadecanal as the active component mediating this inhibitory activity. This chlorinated fatty aldehyde is formed during HOCl-mediated oxidative cleavage of HDL-associated plasmalogen. Conclusion-2-Chlorohexadecanal, produced by the myeloperoxidase-hydrogen peroxide-chloride system of activated phagocytes may act as a mediator of vascular injury associated with ischemia-reperfusion injury, glomerulosclerosis, and atherosclerosis. Key Words: myeloperoxidase Ⅲ 2-chlorinated fatty aldehyde Ⅲ atherosclerosis Ⅲ modified lipids Ⅲ glomerulosclerosis Ⅲ neutrophils A nimal experimentation and clinical studies have provided convincing evidence that the known risk factors for cardiovascular disease can elicit a localized inflammatory response in the vasculature. The changes are most pronounced in endothelial cells and include oxidative stress, increased activation of endothelial signaling pathways, and the consequent adhesion, activation, and degranulation of leukocytes. The myeloperoxidase (MPO)-hydrogen peroxidesystem of stimulated leukocytes, primarily neutrophils, generates hypochlorous acid/hypochlorite (HOCl/Oce Ϫ ), a potent bacterial oxidant in vivo. 1 MPO and HOCl are emerging as critical modulators of vascular injury by promoting inflammatory arterial pathology and subsequent formation of mature plaques. MPO is present and active in human lesion material. 2 HOCl reacts with a wide range of biological substrates, including antioxidants, amines, sulfides, nucleotides, DNA, lipids, and (lipo)proteins. [3][4][5] HOCl-modified (lipo)proteins are present in human 6 -8 and rabbit lesions, 9,10 and disease stage-dependent accumulation of HOCl-modified (lipo)proteins has been reported. 7 Elevated levels of plasma high-density lipoprotein (HDL) protect against atherosclerotic vascular disease. A broad spectrum of potent antioxidant and anti-inflammatory activities has been ascribed to native HDL. 11,12 However, oxidation/modification by HOCl alters the physicochemical and metabolic properties of anti-atherogenic HDL. [13][14][15] In vivo, apolipoprotein A-I, the major apolipoprotein of HDL, represents a selective target for MPO-catalyz...